Bulletin from the Annual General Meeting of SynAct Pharma AB (publ)

Today, 11 May 2017, the Annual General Meeting of SynAct Pharma AB (publ) was held. The following is a summary of the decisions taken. All decisions were taken by the required majority.

Adoption of income statement and balance sheet

The Annual General Meeting resolved to adopt the presented income statement and balance sheet as well as the consolidated profit and loss account and consolidated balance sheet.

Distribution of earnings

The Annual General Meeting resolved to dispose of the company’s losses according to the Board’s proposal in the annual report. The Annual General Meeting also decided that no dividend will be paid for the financial year 2016.

Discharge of liability

The Annual General Meeting resolved to discharge the members of the Board of Directors and the Chief Executive Officer of their liabilities.

Determination of the number of members of the Board of Directors, deputy directors and the number of auditors and determination of remuneration for the Board of Directors and auditors

The General Meeting resolved that there should be four members of the Board of Directors and no deputy board members and that SEK 70,000 be paid to the Chairman of the Board and SEK 50,000 to other members of the Board of Directors, excluding Thomas Jonassen.. In addition, the General Meeting decided that an auditor should be appointed and that remuneration for the auditor should be paid according to the approved account in accordance with customary billing standards.

Election of Board of Directors and auditor

The Annual General Meeting re-elected Lars Adlersson, Torbjørn Bjerke, Charlotte Edenius and Thomas Jonassen as members of the Board of Directors. Torbjørn Bjerke was re-elected Chairman of the Board. Furthermore, the company’s auditor MAZARS SET Revisionsbyrå AB were re-elected until the end of the Annual General Meeting held next financial year.

Decision to amend the Articles of Association  

The General meeting resolved to amend the Articles of Association as follows:

Previous wording Wording adopted
§ 6 Board of DirectorsThe Board of Directors shall comprise a minimum of three and a maximum of eight members, with a maximum of three deputies. § 6 Board of DirectorsThe Board of Directors shall comprise a minimum of four and a maximum of eight members, with a maximum of three deputies.
§ 13 Record date provisionThe shareholder or trustee who, on the record date, is entered in the share register and recorded in a record book, according to section 4, Act (1998:1479) on the accounts of financial instrument or the whoever is recorded on the control account referred to in section 4. 18 § first paragraphs (6) to (8) of that law, is presumed to have the authority to exercise the rights set out in chap. 4 39 § Swedish Companies Act (2005:551). § 12 Record date provisionthe shareholder or trustee who, on the record date, is entered in the share register and recorded in a record book, according to section 4, Act (1998:1479) on central securities depositories and accounting of financial instruments or whoever is recorded on the control account according to
section 4. 18 § first paragraphs (6) to (8) of that law, is presumed to have the authority to exercise the rights set out in chap. 4 39 § Swedish Companies Act (2005:551).

Lund. May 2017

SynAct Pharma AB (publ)

BOARD OF DIRECTORS

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                            Henrik Stage 

CEO, SynAct Pharma AB                                                      CFO, SynAct Pharma AB

Telephone: +45 28 44 75 67                                               Telephone: +45 40 26 09 00
E-mail: joo@synactpharma.com                                        E-mail: hs@synactpharma.com